Avidity Biosciences, Inc. financial data

Symbol
RNA on Nasdaq
Location
10578 Science Center Drive, Suite 125, San Diego, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 10, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.27K % -6.48%
Debt-to-equity 11.9 % -5.86%
Return On Equity -37.7 % -36.3%
Return On Assets -33.7 % -37.2%
Operating Margin -2.93K % +8.55%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 151M shares +26.3%
Common Stock, Shares, Outstanding 147M shares +23.4%
Entity Public Float 4.4B USD +442%
Common Stock, Value, Issued 15K USD +25%
Weighted Average Number of Shares Outstanding, Basic 138M shares +11.8%
Weighted Average Number of Shares Outstanding, Diluted 138M shares +11.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 20.9M USD +106%
Research and Development Expense 488M USD +87.2%
General and Administrative Expense 145M USD +96.1%
Operating Income (Loss) -612M USD -88.6%
Nonoperating Income (Expense) 62.7M USD +41.8%
Net Income (Loss) Attributable to Parent -550M USD -96%
Earnings Per Share, Basic -4 USD/shares -44.6%
Earnings Per Share, Diluted -4 USD/shares -44.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 350M USD -5.41%
Cash, Cash Equivalents, and Short-term Investments 1.2B USD -7.69%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Other Assets, Current 60M USD
Assets, Current 1.97B USD +21.2%
Property, Plant and Equipment, Net 21.5M USD +127%
Operating Lease, Right-of-Use Asset 52.8M USD +739%
Other Assets, Noncurrent 91M USD +28530%
Assets 2.13B USD +30.1%
Accounts Payable, Current 9.63M USD +25.6%
Contract with Customer, Liability, Current 19.1M USD -2.73%
Liabilities, Current 170M USD +86%
Contract with Customer, Liability, Noncurrent 32.1M USD -24.1%
Operating Lease, Liability, Noncurrent 46M USD +1111%
Liabilities 248M USD +80.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.77M USD -75.1%
Retained Earnings (Accumulated Deficit) -1.34B USD -69.5%
Stockholders' Equity Attributable to Parent 1.89B USD +25.5%
Liabilities and Equity 2.13B USD +30.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -125M USD -77.4%
Net Cash Provided by (Used in) Financing Activities 1.94M USD -99.5%
Net Cash Provided by (Used in) Investing Activities 157M USD
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 147M shares +23.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 34.3M USD -88%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 353M USD -5.37%
Deferred Tax Assets, Valuation Allowance 272M USD +57.2%
Deferred Tax Assets, Gross 273M USD +56.1%
Operating Lease, Liability 50M USD
Depreciation 3.42M USD +29%
Payments to Acquire Property, Plant, and Equipment 3.75M USD +310%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -555M USD -104%
Lessee, Operating Lease, Liability, to be Paid 84.1M USD
Property, Plant and Equipment, Gross 32M USD +90.7%
Operating Lease, Liability, Current 3.97M USD +4.29%
Lessee, Operating Lease, Liability, to be Paid, Year Two 7.26M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 8.32M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 34.1M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 9.23M USD
Deferred Tax Assets, Operating Loss Carryforwards 83.4M USD +14.7%
Unrecognized Tax Benefits 22.2M USD +101%
Lessee, Operating Lease, Liability, to be Paid, Year Four 9.51M USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 1.19M USD -39.3%
Share-based Payment Arrangement, Expense 68.6M USD +45.7%